注射用益气复脉(冻干)联合替格瑞洛治疗冠心病心绞痛的疗效观察

目的探究采用注射用益气复脉(冻干)联合替格瑞洛治疗冠心病心绞痛的临床效果与安全性。方法选取商丘市第一人民医院2016年3月—2017年3月收治的冠心病心绞痛患者161例,随机分为对照组(80例)和治疗组(81例)。对照组患者口服替格瑞洛片,首剂量为2片,然后1片/次,2次/d。治疗组患者在对照组基础上静脉滴注注射用益气复脉(冻干),5.2 g加入5%的葡萄糖注射液500 m L,1次/d。两组患者均治疗2周。观察两组患者临床疗效,比较治疗前后两组患者心绞痛症状和评分、血小板聚集率(MPA)、血小板反应指数(PRI)和不良反应情况。结果治疗后,对照组临床总有效率为87.50%,显著低于治疗组的97.53%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者心绞痛发作次数和持续时间均显著减少(P0.05),西雅图心绞痛评分显著升高(P0.05);且治疗组患者各指标改善情况均明显优于对照组(P0.05)。治疗1周后,两组患者的MPA均显著降低、PRI均显著升高,同组比较差异具有统计学意义(P0.05);治疗1周和停药12 h后,治疗组患者MPA和PRI较对照组改善更明显(P0.05)。治疗后,对照组心血管不良事件发生率为10.00%,治疗组为1.23%,两组比较差异具有统计学意义(P0.05)。治疗期间,对照组不良反应发生率为13.75%,显著高于治疗组的2.47%,两组比较差异具有统计学意义(P0.05)。结论注射用益气复脉(冻干)联合替格瑞洛治疗冠心病心绞痛疗效好、安全性高,具有一定的临床推广应用价值。

Clinical observation of Yiqi Fumai (freeze-dried) for injection combined with ticagrelor in treatment of angina pectoris of coronary heart disease

Objective To investigate the clinical efficacy and safety of Yiqi Fumai (freeze-dried) for injection combined with ticagrelor in treatment of angina pectoris of coronary heart disease. Methods Patients (161 cases) with angina pectoris of coronary heart disease in the First People''s Hospital of Shangqiu from March 2016 to March 2017 were randomly divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were po administered with Ticagrelor Tablets, the initial dose was 2 tablets, then 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Yiqi Fumai (freeze-dried) for injection on the basis of the control group, 5.2 g added into 5% Glucose Injection 500 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the angina pectoris symptoms and scores, MPA, PRI and the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 87.50%, which was significantly lower than 97.53% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the frequency and duration of angina pectoris in two groups was significantly decreased (P < 0.05), but SAQ scores were significantly increased (P < 0.05). And the improvement of these indexes in the treatment group after treatment was significantly better than that in the control group (P < 0.05). After treatment for 1 week, MPA in two groups was significantly decreased (P < 0.05), but PRI was significantly increased (P < 0.05). After treatment for 1 week and withdrawal for 12 h, MPA and PRI in the treatment group after treatment were significantly better than those in the control group (P < 0.05). After treatment, the incidence of adverse cardiovascular events in the control group was 10.00%, and the treatment group was 1.23%, with significant difference between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 13.75%, which was significantly higher than 2.47% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Yiqi Fumai for injection (freeze-dried) combined with ticagrelor has significant efficacy in treatment of angina pectoris of coronary heart disease with high safety, which has a certain clinical application value.